Claims

1. Use of a compound selected from the group consisting of Tubastatin A hydrochloride salt, CYC116, TAK-901, Nexturastat A, MI-3, AZ960, and a small interfering RNA molecule comprising any one of SEQ ID No. 5 to SEQ ID No. 28 in the manufacture of a medicament for the treatment of Hepatitis B.

2. The use of the compound according to claim 1, wherein the compound is selected from the group consisting of Tubastatin A hydrochloride salt, CYC116, TAK-901, Nexturastat A, and a small interfering RNA molecule comprising any one of SEQ ID No. 5 to SEQ ID No. 22.

3. The use according to any one of claims 1 or 2, wherein the treatment further comprises administering a nucleoside analogue or pegylated interferon active against a Hepatitis B virus.

4. The use according to claim 3, wherein the nucleoside analogue is selected from the group consisting of entecavir, tenofovir, lamivudine, adefovir, telbivudine, and any prodrug and/or any pharmaceutically salt form of the compounds.

5. A composition comprising a compound selected from the group selected from the group consisting of Tubastatin A hydrochloride salt, CYC116, TAK-901, Nexturastat A, MI-3, AZ960, and a small interfering RNA molecule comprising any one of SEQ ID No. 5 to SEQ ID No. 28; and a nucleoside analogue or pegylated interferon active against a Hepatitis B virus.

6. The composition according to claim 5, wherein the compound is selected from the group consisting of Tubastatin A hydrochloride salt, CYC116, , TAK-901, Nexturastat Aand a small interfering RNA molecule comprising any one of SEQ ID No. 5 to SEQ ID No. 22.

7. The composition according to any one of claims 5 or 6, wherein the nucleoside analogue is selected from the group consisting of entecavir, tenofovir, lamivudine, adefovir, and telbivudine.

8. The composition according to any one of claims 5 to 7, for use as a medicament.

9. The composition according to claim 8, for use in the treatment of Hepatitis B.

10. Use of the composition according to any one of claims 5 to 7 in the manufacture of a medicament for the treatment of Hepatitis B.